Piper Sandler raised the firm’s price target on ImmunityBio (IBRX) to $12 from $7 and keeps an Overweight rating on the shares. The firm notes U.S. ANKTIVA net revenues grew about 700% to $113M in 2025, and Piper now projects $195M in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio: Advancing ANKTIVA Into a Global, Multi-Indication Immunotherapy Platform Supporting a Buy Rating and $15 Target
- IBRX Earnings this Week: How Will it Perform?
- ImmunityBio completes enrollment of Anktiva trial
- ImmunityBio price target raised to $15 from $10 at H.C. Wainwright
- ImmunityBio rises 14.7%